Stage 1: GFR >90

AZURE: Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event

Protocol Name: AZURE: Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event Protocol #: D7960C00015 Indication: Cardiovascular Event Risk Reduction GFR: ≥15 Principal Investigator: Ankit N. Mehta, MD, FASN Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, […]

AZURE: Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event Read More »

Observational Study of Safety and Effectiveness of Elfabrio in Fabry Patients

Protocol Name: Observational Study of Safety and Effectiveness of Elfabrio in Fabry Patients Protocol #: CLI-06657AA1-10 (MODERN) Indication: Fabry Disease GFR: n/a Principal Investigator: Ankit N. Mehta, MD, FASN Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Observational Study of Safety and Effectiveness of Elfabrio in Fabry Patients Read More »

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Protocol Name: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Protocol #: M25-147 ANCHOR Indication: Autosomal Dominant Polycystic Kidney Disease GFR: ≥30 Principal Investigator: Michael R. Wiederkehr, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000,

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Read More »

ASSESS: Double-blind, placebo-controlled, Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome

Protocol Name: ASSESS: Double-blind, placebo-controlled, Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome Protocol #: 22419 Indication: Alport Syndrome GFR: ≥45 Principal Investigator: Ankit Mehta, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS

ASSESS: Double-blind, placebo-controlled, Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome Read More »

Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With ANCA-associated Vasculitis

Protocol Name: Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With ANCA-associated Vasculitis Protocol #: 20220159 Indication: ANCA associated Vasculitis GFR: ≥15 Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With ANCA-associated Vasculitis Read More »

Observational Study Protocol – Fabry Disease Registry

Protocol Name: Observational Study Protocol – Fabry Disease Registry Protocol #: DIREGC07006 Indication: Fabry Disease Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Observational Study Protocol – Fabry Disease Registry Read More »